First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
Sponsor: Gilead Sciences
You may qualify if…
- ✓ 1. Male or non-pregnant, non-breastfeeding female aged 18 years or older
- ✓ 2. Adequate organ function
- ✓ 3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1
- ✓ 4. AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1.
- ✓ 5. For patients with known brain metastases, evidence of clinically stable disease post radiation therapy is required prior to enrollment.
- ✓ 6. For patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1. For patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) the final dose of radiation must have been administered ≥14 days prior to C1D1.
- ✓ 7. Radiologically measurable disease by RECIST v1.1, 4 weeks before C1D1, that can include a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation.
- ✓ 8. Eastern Cooperative Oncology Group (ECOG) 0-1.
You may not qualify if…
- ✕ \-
Where it's recruiting
New Haven
Miami
Boston
Rochester
St Louis
New York
Cleveland · Columbus
Austin · Irving · San Antonio
Seattle
Source: ClinicalTrials.gov · NCT06657222 · last updated 2026-09-11